We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Places Clinical Hold on Sanofi’s BTK Inhibitor in MS and Myasthenia Gravis Trials
FDA Places Clinical Hold on Sanofi’s BTK Inhibitor in MS and Myasthenia Gravis Trials
Phase 3 studies of Sanofi’s tolebrutinib in both multiple sclerosis (MS) and myasthenia gravis have been placed on partial clinical hold following reports of drug-induced liver injury in trial participants.